Aduro Biotech, Inc. today announced the start of the Phase 1 study of ADU-214 , a LADD immuno-oncology therapy for the treatment of lung cancer, with the dosing of the first patient in the trial. Janssen Biotech, Inc., Aduro’s license partner for ADU-214, is conducting the multi-center study.
